血浆置换联合胎肝细胞悬液治疗重型肝炎

目的 :评价中间型人工肝支持系统治疗重型肝炎的疗效。方法 :对 138例重型肝炎患者进行血浆置换联合胎肝细胞悬液治疗 ,5 6例重型肝炎患者采用血浆置换治疗 ,另 48例重型肝炎患者采用胎肝细胞悬液治疗。观察血浆置换联合胎肝细胞悬液治疗患者治疗前后肝功能、氨基酸谱及心肌酶学变化。比较血浆置换联合胎肝细胞悬液治疗与单用血浆置换或胎肝细胞悬液治疗的疗效。结果 :血浆置换联合胎肝细胞悬液治疗较单用血浆置换或胎肝细胞悬液治疗能更有效提高重型肝炎患者好转存活率 ,改善肝功能 ,提高支链氨基酸 (BCAA) /芳香氨基酸 (AAA)比值 ,改善心肌酶学。结论 :血浆置换联合胎肝细胞悬液可有效治疗重型肝炎。

Efficacy of plasma exchange combined with fetal hepacyties on viral hepatitis gravis

Objective To evaluate the efficacy of mid-artificial liver support system (ALSS) on viral hepatitis gravis. Methods One hundred and thirty eight patients with hepatitis gravis were treated with plasma exchange combined with fetal hepacyties, fifty six patients were treated with plasma exchange and other forty eight patients were treated with fetal hepacyties respectively. The liver function was examined in all patients before ALSS. The liver function, amino acid spectrum and cardiac muscle enzyme were examined before and after ALSS in patients treated with plasma exchange and fetal hepacyties. Results It showed that the survival rate of the patients treated with plasma exchange combined with fetal hepacyties was higher than that of the patients only treated with plasma exchange or fetal hepacyties (P<0.01). The liver function, BCAA/AAA ratio and cardiac muscle enzyme also significantly changed in patients treated with plasma exchange and fetal hepacyties before and after ALSS (p<0.01 or 0.05). Conclusion Plasma exchange combined with fetal hepacyties can effectively treat viral hepatits gravis.